Novel Therapeutic Strategies in Diabetes

Dear Colleagues,

Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels, which, if left untreated, can lead to severe complications such as cardiovascular disease, kidney failure, and neuropathy. In recent years, there have been significant advances in diabetes treatment due to a better understanding of the disease's pathophysiology and the development of innovative therapeutic strategies. This Special Issue aims to explore these new therapeutic strategies developed to treat both type 1 and type 2 diabetes more effectively.

One of the most promising research areas is the development of incretin-based therapies. Incretins, such as GLP-1 (glucagon-like peptide-1), are hormones that increase insulin secretion in response to meals. GLP-1 receptor agonists such as liraglutide and semaglutide are popular because they lower blood glucose levels, promote weight loss, and provide cardiovascular benefits. These drugs not only increase insulin secretion but also inhibit the release of glucagon, slow gastric emptying, and reduce appetite. The versatile effects of GLP-1 receptor agonists make them a valuable option for patients with type 2 diabetes, especially those struggling with obesity and cardiovascular risks.

Another novel approach is SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors), which prevent glucose reabsorption in the kidneys, leading to glucose excretion in the urine. Drugs such as empagliflozin and dapagliflozin have shown significant benefits, including a reduced risk of heart failure and progression of kidney disease. These drugs are particularly promising for patients with type 2 diabetes who have cardiovascular or renal comorbidities, as they have a protective effect beyond lowering blood glucose levels.

The advent of immunotherapy has opened new doors in the treatment of type 1 diabetes. Unlike type 2 diabetes, which is primarily characterized by insulin resistance, type 1 diabetes results from an autoimmune attack on the beta cells of the pancreas. Recent advances in immunomodulatory therapies aim to preserve or restore beta cell function. For example, teplizumab, a monoclonal antibody against CD3, has shown the potential to delay the onset of type 1 diabetes in high-risk individuals by modulating the immune response directed against beta cells. Such therapies represent a paradigm shift in the treatment of type 1 diabetes, as they focus on halting the progression of the disease rather than just treating the symptoms.

Gene therapy also holds great promise, particularly for its potential to provide a long-term solution to diabetes management. Recent studies have investigated the possibility of modifying cells outside the pancreas to produce insulin or directly modifying the genes responsible for beta cell dysfunction. While these therapies are still experimental, they could offer a unique treatment that significantly reduces or eliminates the need for insulin therapy.

Another innovative development is artificial pancreas systems that combine continuous glucose monitoring (CGM) with automatic insulin delivery. These closed-loop systems use algorithms to predict glucose trends and adjust real-time insulin delivery. They better mimic the function of a healthy pancreas than conventional insulin pumps. The initial results of clinical studies are promising. They show better control of blood glucose levels and fewer hypoglycemic episodes than conventional insulin therapy.

In addition to these pharmacological and technological innovations, the focus in diabetes treatment is increasingly on personalized medicine. Genomics and metabolomics advances enable customized treatment plans based on an individual's genetic predisposition, lifestyle, and disease progression. Personalized approaches can help optimize the effectiveness of treatment, minimize side effects, and improve the overall quality of life of diabetics.

In summary, the new therapeutic strategies for diabetes significantly advance our ability to treat this complex and prevalent disease. From incretin-based therapies and SGLT2 inhibitors to immunotherapy, gene therapy, and artificial pancreas systems, these innovations offer new hope for patients. As research continues to evolve, even more effective and targeted treatments will likely emerge, potentially transforming diabetes care shortly.

Dr. Aikaterini Andreadi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.